Rybelsus: A First-Line Therapy for Type 2 Diabetes
Key takeaways:
- Rybelsus is an oral diabetes drug approved as a first-line treatment for people with type 2 diabetes.
- It uses the same active ingredient as Ozempic (semaglutide), the difference being that Rybelsus is an oral medication taken daily, while Ozempic is a weekly injection.
- In October 2025, Rybelsus was approved by the FDA to reduce the risk of major adverse cardiovascular events in people with type 2 diabetes.
Rybelsus is a medication called a glucagon-like peptide-1 (GLP-1) receptor agonist. It works by increasing insulin production (which lowers blood glucose) and inhibiting glucagon production (which increases blood glucose) to lower A1C levels.
In 2023, the U.S. Food and Drug Administration (FDA) announced that Rybelsus (semaglutide), an oral GLP-1 medication, could be offered as a first-line treatment option for people with type 2 diabetes. This gave doctors another option to start people on instead of other diabetes medications, such as metformin. In 2025, Rybelsus became the first oral GLP-1 approved to reduce the risk of heart attack, stroke, or cardiovascular-related death in people with type 2 diabetes.
Benefits of Rybelsus
One of the key advantages of Rybelsus is that it is the only approved GLP-1 medication that can be taken as a pill instead of an injection, which makes it more convenient.
In addition to blood sugar management, clinical trials have also found that Rybelsus helps protect the heart. In the PIONEER 6 trial, participants taking Rybelsus experienced cardiovascular protection. Another large trial completed in 2024 found that people with type 2 diabetes and heart disease taking Rybelsus experienced a 14% reduction in major cardiovascular-related events, such as heart attacks and stroke. Since people with diabetes are at a higher risk for heart disease, taking one pill that addresses both high blood sugar and heart health is a helpful option.
In addition, Rybelsus can also help people with type 2 diabetes lose weight. This is because the medication reduces appetite and increase feelings of fullness, which can lead to weight loss. This is especially important for people with type 2 diabetes, as weight management is an important way to prevent complications.
Rybelsus as a first-line treatment
Initially approved in 2019, Rybelsus had a limitation that it should not be used as the initial therapy for treating people with 2 diabetes. A 2023 FDA announcement removed this limitation and updated the prescribing information for Rybelsus.
In conjunction with lifestyle changes, such as eating a healthy diet and getting regular exercise, taking Rybelsus earlier could help people with type 2 diabetes better manage blood sugar levels and help prevent potentially dangerous complications.
Learn more about Rybelsus, semaglutide, and other GLP-1 medications here: